Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYBN SEC filings page on Stock Titan aggregates Cybin Inc.’s regulatory disclosures as a foreign issuer, giving investors structured access to the company’s official documents. Cybin files with the U.S. Securities and Exchange Commission primarily on Form 40-F and Form 6-K, and also uses Form 25 for listing changes. These filings are central to understanding the company’s clinical-stage neuropsychiatry business, its capital structure, and its transition between stock exchanges.
Form 6-K submissions for Cybin typically include interim consolidated financial statements, management’s discussion and analysis, certifications of interim filings, and news releases. Many 6-Ks also incorporate material change reports, equity distribution agreements, and prospectus-related documents by reference into Cybin’s registration statements on Form F-10. For a company developing drug candidates such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, these filings provide context on how clinical programs are funded and governed.
The filings page also features Cybin’s Form 25, which notifies the SEC of the voluntary removal of its common shares from listing and registration on the NYSE American. This document confirms that the company has complied with the exchange’s rules and the requirements for voluntary withdrawal, and it aligns with Cybin’s news release describing its plan to transfer its U.S. listing to the Nasdaq Global Market and to change its trading symbol from CYBN to HELP.
On Stock Titan, each new Cybin filing from EDGAR is captured and presented with AI-powered summaries that explain the purpose and key points of documents such as 6-Ks, F-10 registration statements, and the Form 25 delisting notice. This helps readers quickly understand how Cybin reports its financial results, documents material changes, and manages its listing status, while still allowing direct access to the underlying SEC filings for detailed review.
Deep Track Capital and affiliated entities report owning 2,391,505 Cybin Inc. common shares, representing 4.74% of the class as of December 31, 2025. The position includes 537,250 warrants exercisable into common stock, subject to a 9.99% maximum beneficial ownership limitation.
The ownership calculation uses 50,431,381 shares, based on 49,894,131 common shares outstanding as of December 19, 2025 plus the warrants counted up to the stated cap. The filers certify the holdings are not for the purpose of changing or influencing control of Cybin.
Helus Pharma, formerly Cybin Inc., reported a larger loss but a much stronger balance sheet for the three and nine months ended December 31, 2025. The company, a clinical-stage pharmaceutical developer of novel serotonergic agonists, posted a nine‑month net loss of
Despite the wider loss, liquidity improved significantly. Cash increased to
The company issued and then fully extinguished
Cybin Inc.’s commercial operating unit Helus Pharma has appointed industry veteran Michael Cola as Chief Executive Officer, effective immediately. He brings more than 30 years of experience in neuroscience, rare disease and specialty pharmaceuticals, including leading Shire’s Specialty Pharmaceutical business and senior roles at Astra-Merck and AstraZeneca.
Helus is advancing a pipeline of novel serotonergic agonists for serious mental health disorders, with Phase 2 data for HLP004 expected in the first quarter of 2026 and Phase 3 topline data for HLP003 expected in the fourth quarter of 2026. The company has filed more than 350 patent applications globally and has been granted over 100 patents as it moves from early clinical development toward later-stage execution, global regulatory engagement and long-term commercial planning.
Cybin Inc. has filed a Form 25 to remove its common shares from listing and/or registration on the NYSE American under Section 12(b) of the Securities Exchange Act of 1934. The company states that it has reasonable grounds to believe it meets all requirements for this filing and that the notification has been signed by its Chief Financial Officer, Greg Cavers. This filing starts the formal process for Cybin’s common shares to cease being listed and/or registered on the NYSE American, in accordance with exchange and SEC rules.
Cybin Inc. filed a Form 6-K as a foreign private issuer for December 2025. The report primarily updates investors on corporate documents rather than financial results. Cybin states that Exhibits 99.1 and 99.2 to this Form 6-K are incorporated by reference into its existing Form F-10 shelf registration statement. The exhibit index shows an Equity Distribution Agreement dated December 30, 2025, a consent from Aird & Berlis LLP, and a press release dated December 30, 2025, indicating the company is formalizing distribution arrangements and related legal consents within its Canadian shelf registration framework.
Cybin Inc. is filing a Form F-10 under the multijurisdictional disclosure system to register up to $1,700,000,000 of securities under an amended short form base shelf prospectus, increased from $800,000,000. The shelf covers common shares, warrants, units, debt securities and subscription receipts, which may be offered over a 25‑month period, and also permits secondary sales by selling securityholders. A corresponding U.S. registration statement covers an equivalent of about US$1.23 billion.
The amendment explains that part of the capacity is earmarked to qualify warrant exercises and resale of previously issued shares, and notes a recent registered direct offering and repayment of US$22.8 million of convertible debentures, leaving no loans and borrowings outstanding. Cybin reports cash of about US$202 million as of December 19, 2025 and expects this to fund operations for the next 12 months, including planned spending on its CYB003, CYB004 and CYB005 mental‑health programs, while acknowledging ongoing negative operating cash flow and the likelihood of needing additional capital over time.